doi: 10.1016/B978-0-7020-4087-0.00059-0 190
In a follow-up editorial to the New England Journal of Medicine Study, David Standaert MD PhD from the University of Alabama commented that, Although a variety of physiological effects are observed in response to GLP-1 receptor activation, a consistent finding is reduced inflammation in the brain, a process that is central to the pathophysiology of Parkinsons disease. Have there been other trials of GLP-1 drugs in Parkinsons disease besides Lixisenatide
Its not a number on a scale
Extensive preclinical research shows TB-500 stimulates angiogenesis, promotes wound healing, reduces inflammation, inhibits apoptosis, and enhances tissue perfusion in models of muscle, tendon, ligament, and dermal injury
This also reduces the risk of stomach irritation a common issue with ingredients such as magnesium and makes the format appealing to those who may have difficulty swallowing pills
These researchers looked at kidney disease and cardiovascular disease